World Stroke Congress TASTE-2 significantly reduces disability from stroke

(MENAFN– PR Newswire)

NANJING, China, Oct. 30, 2024 /PRNewswire/ — Oct. 24, 2024, Simcere Pharmaceuticals Group Ltd. (2096) announced that a new clinical study with important clinical findings regarding Sanbexin (concentrated solution for injection of edaravone and dexborneol) has been published in the 16th world stroke conference (WSC). According to the latest data, administration of edaravone dexborneol (Sanbexin®) to patients with acute ischemic stroke (AIS) before endovascular thrombectomy significantly improved the recovery of neurofunction and reduced disability due to stroke.

Professor Yongjun Wang presented a late oral presentation at WCS

The study, entitled “Treatment of acute ischemic stroke with Edaravone dexborneal 2” (“TASTE-2”), presented as a belated oral presentation of WCS by Professor Yongjun Wang of Beijing Tiantan Hospital, has attracted widespread attention in the neurological academic circle in the world.

Stroke is the leading cause of death and disability among adults in China, while AIS accounts for approximately 70% of all strokes. Approximately 40% of AIS patients fall into the category of large vessel occlusion (LVO), a subtype of AIS with higher disability and mortality.

After a stroke, reperfusion treatments (for example, thrombolysis and thrombectomy) are used to restore blood flow to the brain as quickly as possible. Endovascular thrombectomy (EVT), an important advance in reperfusion therapy in recent years, can achieve recanalization in approximately 70% to 90% of patients with LVO stroke, but only half of these patients achieve favorable recovery of the stroke. brain function. patients who received EVT remain disabled to varying degrees after 90 days of treatment.

The TASTE-2 study is a multicenter, double-blind, randomized, placebo-controlled clinical trial. From March 2022 to May 2023, a total of 1362 AIS patients with large vessel occlusion (LVO) in the anterior circulation were included. Patients were randomly assigned (1:1) to receive edaravone dexborneol (edaravone, 30 mg; (+)-dexborneol, 7.5 mg) or placebo prior to EVT twice daily for a consecutive period of 10-14 days to continue.
As a primary efficacy outcome, 379 (55.0%) patients in the edaravonedexborneol group and 333 (49.6%) in the placebo group achieved an mRS 0-2 at day 90 (odds ratio (OR) 1.24, 95% CI 1.00 – 1.54; risk ratio (RR) 1.11, 95% CI 1.00-1.23). All safety results were comparable between both groups. This suggests that Edaravone dexborneol could improve favorable functional outcome at 90 days in AIS patients within 24 hours of symptom onset undergoing EVT.

Sanbexin® (Edaravone dexborneol concentrated solution for injection) is a multi-targeted brain cell protection agent developed by Simcere Pharmaceutical Co., Ltd, and is
the only approved innovative drug in the field of stroke treatment worldwide since 2015. Composed of edaravone and dexborneol, two active ingredients with synergistic antioxidant and anti-inflammatory effects, the drug can significantly reduce brain cell damage or damage caused by AIS.

According to the recommendations of the Stroke Academic Roundtable Meeting (STAIR), brain cytoprotectants may reduce ischemic brain injury, especially when combined with thrombectomy. The scientific community has also been working for decades on brain cytoprotective agents for the treatment of stroke. However, due to the complexity of stroke pathophysiology, single-target drugs have proven to have limited efficacy and are difficult to develop clinically.

On the other hand, the clinical study of multi-target brain cytoprotectants continues to progress. Previously, the TASTE study led by Professor Yongjun Wang’s team at Beijing Tiantan Hospital and the TASTE-SL study led by Professor Dongsheng Fan at Beijing University Third Hospital confirmed the efficacy of edaravone injection dexborneol and sublingual tablets in AIS patients not receiving reperfusion treatment. . The latest results from the TASTE-2 study provide important clinical medical evidence for Sanbexn® as a multi-target brain cell protection strategy in combination with reperfusion in the treatment of acute ischemic stroke. Sanbexin® is expected to be used as a concomitant drug for endovascular treatment such as thrombectomy, especially before reperfusion, to further improve the effect of stroke treatment and reduce stroke disability.

SOURCE Simcere Pharmaceutical Group Limited

Would you like to display your company’s news on PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital media
Points of sale 270k+
Journalists
Registered GET STARTED

MENAFN30102024003732001241ID1108832232

Legal disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.